trimetrexate has been researched along with Glial Cell Tumors in 3 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The National Cancer Institute of Canada Clinical Trials Group conducted a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable recurrent anaplastic glioma and limited prior treatment." | 7.68 | Phase II study of trimetrexate in recurrent anaplastic glioma. National Cancer Institute of Canada Clinical Trials Group Study. ( Cairncross, JG; Eisenhauer, EA; Kerr, IG; MacCormick, RE; Macdonald, DR; Moore, MJ; Rathbone, MP; Sawka, CA, 1990) |
| "The present study describes the effects of 2 folate antagonists, methotrexate (MTX) and the lipophilic antifolate trimetrexate (TMX) on 2 permanent human glioma cell lines (GaMg and D-54Mg) grown as monolayers and as multicellular tumor spheroids." | 3.68 | Proliferation, migration and invasion of human glioma cells exposed to antifolate drugs. ( Arnold, H; Bjerkvig, R; Fiskerstrand, T; Refsum, H; Terzis, AJ; Ueland, PM, 1993) |
| "The National Cancer Institute of Canada Clinical Trials Group conducted a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable recurrent anaplastic glioma and limited prior treatment." | 3.68 | Phase II study of trimetrexate in recurrent anaplastic glioma. National Cancer Institute of Canada Clinical Trials Group Study. ( Cairncross, JG; Eisenhauer, EA; Kerr, IG; MacCormick, RE; Macdonald, DR; Moore, MJ; Rathbone, MP; Sawka, CA, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pappo, AS | 1 |
| Vats, T | 1 |
| Williams, TE | 1 |
| Bernstein, M | 1 |
| Kamen, BA | 1 |
| Terzis, AJ | 1 |
| Fiskerstrand, T | 1 |
| Refsum, H | 1 |
| Ueland, PM | 1 |
| Arnold, H | 1 |
| Bjerkvig, R | 1 |
| Cairncross, JG | 1 |
| Eisenhauer, EA | 1 |
| Macdonald, DR | 1 |
| Rathbone, MP | 1 |
| Moore, MJ | 1 |
| Sawka, CA | 1 |
| MacCormick, RE | 1 |
| Kerr, IG | 1 |
1 trial available for trimetrexate and Glial Cell Tumors
| Article | Year |
|---|---|
Phase I trial of trimetrexate in pediatric solid tumors: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Brain Neoplasms; Carcinoma, Renal Cell; Child; Child, Preschool; Female; Follow-U | 1993 |
2 other studies available for trimetrexate and Glial Cell Tumors
| Article | Year |
|---|---|
Proliferation, migration and invasion of human glioma cells exposed to antifolate drugs.
Topics: Animals; Brain; Cell Division; Cell Movement; Cytotoxins; Folic Acid Antagonists; Glioma; Humans; In | 1993 |
Phase II study of trimetrexate in recurrent anaplastic glioma. National Cancer Institute of Canada Clinical Trials Group Study.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Drug Evaluation; Female; Glioma; Humans; Injections, Int | 1990 |